Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Pharmacogenomics|May 7, 2014
A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patientsMina Maftouh, Amir Avan, Niccola Funel, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|April 26, 2021
Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patientsDavide Melisi, Alessandro Cavaliere, Stefano Gobbo, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|July 3, 2021
Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trialIsabella Frigerio, Salvatore Paiella, Emilio Barbi, et al.
JAMA Oncology|February 14, 2020
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical TrialFausto Petrelli, Roberto Labianca, Alberto Zaniboni, et al.
The Journal of Liquid Biopsy|March 3, 2025
Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancerLenka N C Boyd, Mahsoem Ali, Jisce R Puik, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2021
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trialGerardo Rosati, Sara Lonardi, Fabio Galli, et al.
Carcinogenesis|August 7, 2016
Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patientsCosmeri Rizzato, Daniele Campa, Renata Talar-Wojnarowska, et al.
The Lancet. Oncology|March 14, 2020
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trialChiara Cremolini, Carlotta Antoniotti, Daniele Rossini, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 5, 2012
Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortiumDaniele Campa, Cosmeri Rizzato, Gabriele Capurso, et al.
Scientific Reports|March 9, 2017
SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survivalBeatrice Mohelnikova-Duchonova, Ondrej Strouhal, David J Hughes, et al.
Pageof 7